Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.18 USD | +0.02% | +6.54% | -14.53% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.53% | 2.52B | |
+32.73% | 50.85B | |
+0.07% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.83% | 26.11B | |
-22.26% | 19.13B | |
+8.37% | 13.05B | |
+27.21% | 12.16B | |
+24.42% | 12.08B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics Says Application for Investigational Transthyretin Amyloidosis Treatment Cleared by FDA